Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when AVXL files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Delisting (new) — Company received formal Nasdaq notice of non-compliance due to late quarterly filing, triggering potential delisting process.
Anavex receives Nasdaq delisting notice for late Q1 filing; has until July to submit plan
Filed May 22, 2026 · Period ending May 20, 2026 · ~1 min read
Key Changes
-
high
Nasdaq notified Anavex on May 20 that it violated listing rules by failing to file its Q1 2026 quarterly report on time. The stock continues trading under AVXL but faces potential delisting.
Item 8.01 verify on EDGAR → -
high
Company has until July 20, 2026 to submit a compliance plan. If Nasdaq accepts the plan, Anavex could receive up to 180 days (until November 16, 2026) to file the overdue report and regain compliance.
Item 8.01 verify on EDGAR → -
medium
Management states it is working to complete the Q1 filing and prepare a compliance plan, but provided no explanation for the delay or expected completion date.
Item 8.01 verify on EDGAR →
Summary
Anavex Life Sciences disclosed that Nasdaq has formally notified the company of non-compliance with listing rules after it failed to file its first-quarter 2026 earnings report on time. The notice, received May 20, does not immediately delist the stock, which continues trading normally under ticker AVXL.
However, the company now faces a two-step compliance process: submit a remediation plan by July 20, then potentially receive up to six months to actually file the overdue quarterly report. For retail investors, this raises immediate questions about what's causing the delay.
The company offered no explanation for missing the filing deadline—whether it's an accounting issue, auditor problems, or internal control weaknesses. The lack of transparency is concerning. While many companies successfully navigate these Nasdaq notices, the silence around the root cause is a yellow flag. Watch for either the Q1 filing itself or any subsequent 8-K disclosures about material weaknesses, restatements, or management changes that might explain the holdup.
Section-by-Section Diff
Event · Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 20, 2026, Anavex Life Sciences Corp. (the “Company”) received a delinquency notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s inability to timely file its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026 (the “Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c) (1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission.
The company received a formal deficiency notice from Nasdaq on May 20, 2026 for failing to file its Q1 2026 quarterly report on time. This violates Nasdaq Listing Rule 5250(c)(1), which mandates timely filing of all required SEC reports. The notice does not immediately delist the stock, which continues trading under symbol AVXL.
Added in current filing · verify on EDGAR →
As indicated in the Notice, the Company has until July 20, 2026, to submit a plan to regain compliance. If Nasdaq accepts the Company’s plan, it may grant an exception of up to 180 calendar days from the Form 10-Q’s due date, or until November 16, 2026, for the Company to regain compliance.
The company has until July 20, 2026 to submit a compliance plan to Nasdaq. If accepted, Nasdaq may grant up to 180 days from the original filing deadline (extending to November 16, 2026) for the company to file the overdue quarterly report and regain compliance. If the plan is rejected, the company can appeal to a Nasdaq Hearings Panel.
Event · Item 8.01 — Other Events
Company received Nasdaq notice regarding delayed Form 10-Q filing; plans to submit compliance plan to regain listing rule compliance.
Added in current filing · verify on EDGAR →
the Company’s receipt of the Notice
The company received a notice from Nasdaq, referenced in a press release issued May 22, 2026. The notice relates to non-compliance with Nasdaq Listing Rule 5250(c)(1), which governs timely filing of periodic reports. The company plans to file its delayed Form 10-Q and submit a compliance plan to Nasdaq.
Added in current filing · verify on EDGAR →
the Company’s plans to complete and file the Form 10-Q and to submit a plan to regain compliance with Nasdaq Listing Rule 5250(c) (1)
The company has not yet filed its Form 10-Q quarterly report as required under Nasdaq listing rules. Management states it plans to complete and file the Form 10-Q and submit a compliance plan to Nasdaq to regain compliance with Rule 5250(c)(1), which requires timely periodic filings.
Event · Item 9.01 — Financial Statements and Exhibits
Anavex filed an 8-K attaching a press release dated May 22, 2026; no material business event disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Exhibit No. | Description | 99.1 | Press Release dated May 22, 2026.
The 8-K references an attached press release dated May 22, 2026 (Exhibit 99.1). The filing body itself contains no substantive disclosure about the event; all material information would be in the press release exhibit, which is not included in this filing text.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 28, 2026 · How we verify